Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD-Reference-Cited by-同舟云学术

Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD

Published:2017-10 Issue: Volume:46 Page:69-77
ISSN:1094-5539
Container-title:Pulmonary Pharmacology & Therapeutics
language:en
Short-container-title:Pulmonary Pharmacology & Therapeutics

Author:

Cahn A.,Hamblin J.N.,Begg M.,Wilson R.,Dunsire L.,Sriskantharajah S.,Montembault M.^ORCID,Leemereise C.N.,Galinanes-Garcia L.,Watz H.,Kirsten A.M.^ORCID,Fuhr R.,Hessel E.M.

Funder

Kate Hollingworth of Continuous Improvement Ltd

GSK

Publisher

Elsevier BV

Subject

Pharmacology (medical),Biochemistry, medical,Pulmonary and Respiratory Medicine

Reference24 articles.

1. From the Global Strategy for the Diagnosis, Management and Prevention of COPD,2016

2. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010;Lozano;Lancet,2012

3. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010;Murray;Lancet,2012

4. Pathogenesis of chronic obstructive pulmonary disease;Tuder;J. Clin. Invest,2012

5. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease;Wedzicha;BMC Med.,2013

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrated network pharmacology and pharmacological investigations to explore the potential mechanism of Ding-Chuan-Tang against chronic obstructive pulmonary disease;Journal of Ethnopharmacology;2024-06

2. Efficacy of Nemiralisib in Chronic Obstructive Pulmonary Disease: A Systematic Review;Clinical Therapeutics;2024-04

3. Role of thioredoxin in chronic obstructive pulmonary disease (COPD): a promising future target;Respiratory Research;2023-11-24

4. Discovery of Highly Selective and Orally Bioavailable PI3Kδ Inhibitors with Anti-Inflammatory Activity for Treatment of Acute Lung Injury;Journal of Medicinal Chemistry;2023-08-22

5. An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome;Pulmonary Pharmacology & Therapeutics;2023-04